Details of the Drug Combinations

General Information of This Drug (ID: DMB1IU4)

Drug Name
Lenvatinib   DMB1IU4
Synonyms E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
Indication
Disease Entry ICD 11 Status REF
Thyroid cancer 2D10 Approved [1]
Thyroid gland follicular carcinoma N.A. Approved [2]
Thyroid gland papillary carcinoma N.A. Approved [2]
Hepatocellular carcinoma 2C12.02 Phase 3 [3]
Renal cell carcinoma 2C90 Phase 3 [4]
Melanoma 2C30 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
Ovarian cancer 2C73 Phase 1 [5]
Non-small-cell lung cancer 2C25.Y Application submitted [4]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

12 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
(-)-englerin A + Lenvatinib DCPQHMH (-)-englerin A Ewing sarcoma (Cell Line: TC-71) [6]
Exherin + Lenvatinib DCM0Y6O Exherin Ewing sarcoma (Cell Line: TC-71) [6]
Lenvatinib + GSK461364 DCQD4LB GSK461364 Ewing sarcoma (Cell Line: TC-71) [6]
Lenvatinib + BN-2629 DCDUNDR BN-2629 Ewing sarcoma (Cell Line: TC-71) [6]
Lenvatinib + Daporinad DCX0WFU Daporinad Ewing sarcoma (Cell Line: TC-71) [6]
Lenvatinib + Docetaxel DC91SOL Docetaxel Ewing sarcoma (Cell Line: TC-71) [6]
LY2874455 + Lenvatinib DCNYEMT LY2874455 Ewing sarcoma (Cell Line: TC-71) [6]
NVP-AUY922 + Lenvatinib DCJLPYK NVP-AUY922 Ewing sarcoma (Cell Line: TC-71) [6]
Ombrabulin + Lenvatinib DCDNEG8 Ombrabulin Ewing sarcoma (Cell Line: TC-71) [6]
OSI-906 + Lenvatinib DCPCA8D OSI-906 Ewing sarcoma (Cell Line: TC-71) [7]
Panobinostat + Lenvatinib DCIJUOA Panobinostat Ewing sarcoma (Cell Line: TC-71) [6]
THAPSIGARGIN + Lenvatinib DCJ6HGL THAPSIGARGIN Ewing sarcoma (Cell Line: TC-71) [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)
11 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Eribulin + Lenvatinib DC9R60D Eribulin Leiomyosarcoma [8]
Lenvatinib + Mebendazole DC0FGIQ Mebendazole Hepatocellular Carcinoma [9]
Lenvatinib + E-7050 DCL2R70 E-7050 Advanced Solid Tumors [10]
Lenvatinib + Cabozantinib DCSRGUI Cabozantinib Differentiated Thyroid Gland Carcinoma [11]
Lenvatinib + Capecitabine DC43E9B Capecitabine Advanced Cancer [12]
Lenvatinib + Axitinib DC4BPE4 Axitinib Advanced Renal Cell Carcinoma [13]
Lenvatinib + Raltitrexed DCIF7BU Raltitrexed Hepatocellular Carcinoma Stage IIIa [14]
Lenvatinib + Erlotinib DCJZXID Erlotinib Neoplasms [15]
Eribulin + Lenvatinib DC95HHD Eribulin Cancer [16]
Everolimus + Lenvatinib DCIHQEK Everolimus Renal Cell Carcinoma [17]
Everolimus + Lenvatinib DCFFWWH Everolimus Renal Cell Carcinoma [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
2 Lenvatinib FDA Label
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
6 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
7 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
8 ClinicalTrials.gov (NCT03526679) Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
9 ClinicalTrials.gov (NCT04443049) To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
10 ClinicalTrials.gov (NCT01433991) A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
11 ClinicalTrials.gov (NCT02592356) Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
12 ClinicalTrials.gov (NCT02915172) Lenvatinib and Capecitabine in Patients With Advanced Malignancies
13 ClinicalTrials.gov (NCT04522323) A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
14 ClinicalTrials.gov (NCT05007587) Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
15 ClinicalTrials.gov (NCT06161558) Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
16 ClinicalTrials.gov (NCT02640508) Eribulin and Lenvatinib in Advanced Solid Tumors
17 ClinicalTrials.gov (NCT03173560) Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
18 ClinicalTrials.gov (NCT02811861) Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma